(6-methoxy-1,3-benzothiazol-2-yl)(3-methoxy-4-phenoxyphenyl)methanone | 1361253-11-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (6-methoxy-1,3-benzothiazol-2-yl)(3-methoxy-4-phenoxyphenyl)methanone
• 英文别名: (6-Methoxy-1,3-benzothiazol-2-yl)-(3-methoxy-4-phenoxyphenyl)methanone
• CAS: 1361253-11-3
• 化学式: C₂₂H₁₇NO₄S
• 分子量: 391.447
• InChiKey: NREQURMCYKVNCU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  85.9
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (6-methoxy-1,3-benzothiazol-2-yl)(3-methoxy-4-phenoxyphenyl)methanone 在 三溴化硼 作用下， 以 二氯甲烷 为溶剂， 反应 20.0h， 以84%的产率得到(6-hydroxy-1,3-benzothiazol-2-yl)(3-hydroxy-4-phenoxyphenyl)methanone
  参考文献：
  名称：

  Optimization of Hydroxybenzothiazoles as Novel Potent and Selective Inhibitors of 17β-HSD1

  摘要：

  17 beta-HSD1 is a novel target for the treatment of estrogen-dependent diseases, as it catalyzes intracellular estradiol formation. Starting from two recently described compounds, highly active and selective inhibitors were developed. Benzoyl 6 and benzamide 17 are the most selective compounds toward 17 beta-HSD2 described so far. They also showed a promising profile regarding activity in T47-D cells, selectivity toward ER alpha and ER beta inhibition of hepatic CYP enzymes, metabolic stability, and inhibition of marmoset 17 beta-HSD1 and 17 beta-HSD2.

  DOI：

  10.1021/jm201711b
• 作为产物：
  描述：

  O-tert-butyldimethylsilylvanillin 在 正丁基锂 、 四丁基氟化铵 、 copper diacetate 、 2-碘酰基苯甲酸 作用下， 以 四氢呋喃 、 正己烷 、 二氯甲烷 为溶剂， 反应 41.25h， 生成 (6-methoxy-1,3-benzothiazol-2-yl)(3-methoxy-4-phenoxyphenyl)methanone
  参考文献：
  名称：

  Optimization of Hydroxybenzothiazoles as Novel Potent and Selective Inhibitors of 17β-HSD1

  摘要：

  17 beta-HSD1 is a novel target for the treatment of estrogen-dependent diseases, as it catalyzes intracellular estradiol formation. Starting from two recently described compounds, highly active and selective inhibitors were developed. Benzoyl 6 and benzamide 17 are the most selective compounds toward 17 beta-HSD2 described so far. They also showed a promising profile regarding activity in T47-D cells, selectivity toward ER alpha and ER beta inhibition of hepatic CYP enzymes, metabolic stability, and inhibition of marmoset 17 beta-HSD1 and 17 beta-HSD2.

  DOI：

  10.1021/jm201711b

文献信息

• [EN] SELECTIVE 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS<br/>[FR] INHIBITEURS SÉLECTIFS DE LA 17-BÊTA-HYDROXYSTÉROÏDE DÉSHYDROGÉNASE DE TYPE 1
  申请人：UNIV SAARLAND

  公开号：WO2012025638A1

  公开（公告）日：2012-03-01

  The invention relates to selective, non-steroidal 17beta-hydroxysteroid dehydrogenase type 1 (17β-HSD1) inhibitors their production and use, especially for the treatment and/or prophylaxis of hormone-related diseases.

  这项发明涉及选择性的、非类固醇17β-羟基类固醇脱氢酶1型（17β-HSD1）抑制剂的生产和使用，特别用于治疗和/或预防激素相关疾病。
• Optimization of Hydroxybenzothiazoles as Novel Potent and Selective Inhibitors of 17β-HSD1
  作者：Alessandro Spadaro、Martin Frotscher、Rolf W. Hartmann

  DOI：10.1021/jm201711b

  日期：2012.3.8

  17 beta-HSD1 is a novel target for the treatment of estrogen-dependent diseases, as it catalyzes intracellular estradiol formation. Starting from two recently described compounds, highly active and selective inhibitors were developed. Benzoyl 6 and benzamide 17 are the most selective compounds toward 17 beta-HSD2 described so far. They also showed a promising profile regarding activity in T47-D cells, selectivity toward ER alpha and ER beta inhibition of hepatic CYP enzymes, metabolic stability, and inhibition of marmoset 17 beta-HSD1 and 17 beta-HSD2.